This is an essential observation, as IL-17A was previously shown to exacerbate inflammation in IBD, whereas IL-22-secreting ILC3s have been described to be beneficial for IBD patients, leukemic patients after HSCT, and GI tract transplant recipients (15, 21, 25, 27, 48–50). The gene discussed is IL17A; the disease is inflammatory bowel disease.